Clinical Trial Update: Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) [Phase 1]

View source ↗

Summary

Phase 1 study ENGAGER-PSMA-01 evaluating JANX007 in metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• JANX007

Snippet

Sponsor: Janux Therapeutics | Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: RECRUITING